Immuneering Corporation
IMRX
$5.05
-$0.40-7.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -0.32% | 4.86% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.58% | 4.22% | |||
| Operating Income | 10.58% | -4.22% | |||
| Income Before Tax | 22.62% | -3.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 22.62% | -3.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 22.62% | -3.68% | |||
| EBIT | 10.58% | -4.22% | |||
| EBITDA | 10.62% | -4.28% | |||
| EPS Basic | 52.47% | 5.96% | |||
| Normalized Basic EPS | 51.82% | 5.94% | |||
| EPS Diluted | 52.47% | 5.96% | |||
| Normalized Diluted EPS | 51.82% | 5.94% | |||
| Average Basic Shares Outstanding | 62.82% | 10.24% | |||
| Average Diluted Shares Outstanding | 62.82% | 10.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||